Drug Development Clinical Trials
The purpose of preclinical work--animal pharmacology/toxicology testing--is to develop adequate data to undergird a decision that it is reasonably safe to proceed with human trials of the drug. After satisfactory information has been collected on the quality of the non-clinical safety, and Health Authority/Ethics Committee approval is granted, clinical trials are conducted to evaluate its safety and effectiveness in treating, preventing, or diagnosing a specific disease or condition. The results of this testing will comprise the single most important factor in the approval or disapproval of a new drug.

Although the goal of clinical trials is to obtain safety and effectiveness data, the overriding consideration in these studies is the safety of those in the trials. CDER monitors the study design and conduct of clinical trials to ensure that people in the trials are not exposed to unnecessary risks.

Below find legal and ethical regulations and guidance that the US FDA published for the clinical trial of drug development:

Ethics Review
(Needs link) 

Regulatory Review IND
Information for investigators about submitting Investigational New Drug (IND) applications to FDA
Guidance for Industry: Content and Format of Investigational
New Drug Applications (INDs) for Phase 1 studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products
Questions and Answers:  Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products
Exploratory IND Studies

Phase I
Guidance for Industry cGMP for Phase 1 Investigational Drugs

Long-term /Reproductive Toxicity
Guidance for Industry: the Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals 
Guidance on the Duration of Chronic Toxicity Testing in Animals (Rodent and Non-rodent Toxicity Testing); Availability - THIS IS OLD
Guideline for Industry Detection of Toxicity to Reproduction for Medicinal Products - THIS IS OLD
Reviewer Guidance: Integration of Study Results to Assess Concerns about Human Reproductive and Developmental Toxicities

In vivo Metabolism
(Needs link)

Phase II and Phase III
Guidance for Industry: INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information
End-of-phase 2A meetings
U.S. Food and Drug Administration Center for Drug Evaluation and Research Handbook

Next Page - FDA Filing/Approval for Drugs


NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.